José Sandoval

We were awarded the Ferenc Bojan Young Investigator Award at the @EPHconference. Happy that our work got recognised and the Bus Santé is continuing to produce relevant public health research. @iguessous @Hopitaux_unige @unige_en @UNIGEnews

Ocafu's Tortilla, as suggested by @JavierCortesMD. Thanks for the great gourmet suggestion and mentorship over these last 3 days.

@PTarantinoMD Also new biomarkers/test are quickly patented and developed for profit, making the use of public money to pay these trials more questionable. IMO it requires a mix of gvt/insurance companies funding and a commitment to fair pricing if test/biomarker is clinically useful.

In the 1970s, we started giving adjuvant chemo to most pts with breast cancer. It took 40y to validate a biomarker to identify which patients really benefit from chemo. Hopefully, it won’t take so long to understand which pts actually benefit from (neo)adjuvant IO, ADCs, CDK4/6i.

@PTarantinoMD Agree. The problem is that the cost of clinical utility trials is enormous and and even more for NI trials. There's no interest (understandably so) from pharma to invest in this topic as it would reduce their market.

#ESMO25 So nice to see my friend and colleague @JLSandoval co-chairing with Carolien Schröder a session focusing on tailoring breast cancer care for special populations.👍👏 @DOncologie @hug_ge

@ajumathew_ @Cambridge_Uni @CaiusCollege @ClareCollege , not very far ;)

@JLSandoval @Cambridge_Uni I was at Gonville & Caius @CaiusCollege You?

Wow. That’s from the lab of my classmate during MPhil days in @Cambridge_Uni Quite cool when I see people I once studied or worked with and now creating or breaking ground in science and research.

Congratulations @JLSandoval et al. for this study exploring biomarkers in ovarian cancer! Very nice collaborative effort, well done 👍 👏#ASCO25 @hug_ge @institut_curie !

Interesting data from PADA-1 trial at #esmobreast25 by FC Bidard @institut_curie Rate of ESR1m detection changes over time suggesting selection of a subclone rather than ESR1m emergence, factors associated with ESR1m detection were identified. Same for ESR1m detection w/o PD.

Which companies are driving the future of #BreastCancer treatment? @Larvol CLIN highlights the innovators who stood out at @SABCSSanAntonio 2024. Discover more: t.ly/24Mrr #LARVOL #SABCS24 #Oncology #CancerResearch #CancerData #CancerCare #OncologyUpdates

Discover key discussions and reactions on top trials from @SABCSSanAntonio 2024 with @Larvol CLIN. Learn More: t.ly/24Mrr #LARVOL #SABCS24 #Oncology #CancerResearch #BreastCancer #CancerData #CancerCare #OncologyUpdates

Wrapping up another fantastic #SABCS! Amazing, practice-changing data were presented. I’ve updated the algorithms and added key studies from the meeting— I finally ran out of space in HR+ disease! #SABCS24 @OncoAlert

📡SOLTI-2103 VALENTINE Trial: Phase II Trial of Neoadjuvant Patritumab Deruxtecan vs. Chemotherapy for High-Risk HR+/HER2- Early Breast Cancer The SOLTI-2103 VALENTINE trial at SABCS 2024 highlighted the promising potential of HER3-DXd in neoadjuvant treatment for high-risk HR+/HER2- early breast cancer, showing comparable pathological complete response rates to chemotherapy, but further follow-up is needed to assess its impact on event-free survival and quality of life. @MOliveira_MD @_SOLTI @stolaney1 @GaiaGriguolo @SuyogCancer @puneetsinghmd @JLSandoval Discover more about the SOLTI VALENTINE trial and its potential in breast cancer treatment: oncodaily.com/blog/valentine… #BreastCancer #OncoDaily #Oncology #SABCS24 #MedEd #MedX #MedNews #Medicine

CamRelief, early TNBC, NACT +/- periop Camrelizumab (#SABCS24): - Cape allowed. - pCR rate improved (12% delta). - No EFS benefit yet (immature). Looking similar to GeparDouze. Diff with KN522 a question of anti-PD-1 vs anti-PD-L1, or cape being permitted? Both? Asian patients?

GeparDouze trial in early TNBC, NACT +/- periop Atezo at #SABCS24: - No EFS benefit - Cape allowed from Feb 2020 (why not earlier?) - No clear EFS differences by pCR status. Another negative trial for Atezo. How would KN522 results have differed if Cape had been allowed? 🤔

Anthracyclines in High Genomic Risk N0 HR+/HER2- EBC in TAILORx (#SABCS24): - RS 31 cutoff predicts 5y DRFI benefit with Anthra -mainly in postmenopausal (OFS effect?). - Note: ttt not randomised. 🧠 Vogl NY asks: Could Ki67 offer similar predictive insights?🙃

ZEST trial: Niraparib in patients with MRD (ctDNA+ during ctDNA surveillance) EBC (TNBC or tBRCA+) (#SABCS24): - Only 147/1901 patients had ctDNA+, 40 randomised - 800 to be randomised - study terminated Cautionary tale on the challenges of doing MRD-guided RCTs in EBC.

PATINA trial in HER2+ ER+ MBC, Trast+Pert+ET +/- Palbociclib (#SABCS24): - PFS benefit: 44 vs 29 months👏 - No clear OS benefit - Worse toxicity profile. DB09 data in 6 months and T-DXd likely moving to 1L. the future role of PATINA uncertain. Complex decisions ahead!🤔

Important study from EBCCTG on obesity & prognosis in EBC (#SABCS24): - Strong link: Worse outcomes with higher BMI. - Especially impactful in premenopausal women. - Independent of LN and ER status. A stark reminder of the broader consequences of the obesity epidemic. 🌍

COMET trial, active monitoring vs surgery (+/-RT) in low risk DCIS at #SABCS24 : - 2y IBC rate non-inferior (dif: 1.7%) - most got Adj ET - 31% women didn't adhere to randomisation, favouring AM But is QoL better than surgery + RT w/o ET? jamanetwork.com/journals/jama/…

Key insights for "Good Risk" DCIS patients with BCS and forgoing Adj RT at #SABCS24 : - Adjuvant tamoxifen shows invasive IBR benefit. - No difference in contralateral breast events noted. Crucial data for informed discussions on de-escalating RT vs ET in DCIS management. 🤝